Evidence map›Paper›PMID 28811965›Full record

ArticleOncoimmunology

Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study.

Jeong-Hoon Lee, Won Young Tak, Yoon Lee, Min-Kyu Heo, Jae-Sung Song, Hak-Yeop Kim, Soo Young Park, Si Hyun Bae, Joon Hyeok Lee, Jeong Heo and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jeong-Hoon LeeDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Won Young TakDepartment of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Yoon LeeDepartment of Biological Science, Sungkyunkwan University, Suwon, Korea.
Min-Kyu HeoJW CreaGene Research Institute, JW CreaGene Inc., Seongnam-si, Gyeonggi-do, Korea.
Jae-Sung SongJW CreaGene Research Institute, JW CreaGene Inc., Seongnam-si, Gyeonggi-do, Korea.
Hak-Yeop KimJW CreaGene Research Institute, JW CreaGene Inc., Seongnam-si, Gyeonggi-do, Korea.
Soo Young ParkDepartment of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Si Hyun BaeThe Catholic University Liver Research Center, The Catholic University of Korea, Seoul, Korea.
Joon Hyeok LeeSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jeong HeoDepartment of Internal Medicine, Pusan National University School of Medicine, Busan, Republic of Korea.
Ki-Hwan KimJW CreaGene Research Institute, JW CreaGene Inc., Seongnam-si, Gyeonggi-do, Korea.
Yong-Soo BaeDepartment of Biological Science, Sungkyunkwan University, Suwon, Korea.
Yoon Jun KimDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our previous phase I/IIA study showed that autologous dendritic cells (DCs) pulsed with tumor-associated antigens are well tolerated in patients with hepatocellular carcinoma (HCC). In this randomized, multicenter, open-label, phase II trial, we investigated the efficacy and safety of this DC-based adjuvant immunotherapy with 156 patients, who treated for HCC with no evidence of residual tumor after standard treatment modalities. Patients were randomly assigned to immunotherapy (

Indexed as

Adjuvant immunotherapybiomarkerdendritic cell vaccinehepatocellular carcinomarecurrence-free survival

Identifiers

PMID28811965
PMCPMC5543846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.